Santo Costa - Cytokinetics Independent Director


USD 47.25  0.22  0.46%   

Mr. Santo Joseph Costa is Independent Director of the Company. Mr. Costa has served as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina, specializing in corporate law for healthcare companies. From 1994 to 2001, he held various positions at Quintiles Transnational Corporationrationration, including as Vice Chairman, President and Chief Operating Officer. Prior to joining Quintiles, Mr. Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President, Administration with Glaxo Inc. Prior to joining Glaxo, he served as U.S. Area Counsel with Merrell Dow Pharmaceuticals and as Food Drug Counsel with Norwich Eaton Pharmaceuticals, Inc. Mr. Costa has served as Chairman of the Board of Alchemia Limited, a biopharmaceutical company, from March 2014 to June 2015. He served on the Board of Directors of Magor Corporationrationration, formerly Biovest Corporationration I, from March 2010 until March 2013. He served as Chairman of the Board of LaboPharm, Inc. from 2006 to 2011 and a director of OSI Pharmaceuticals from 2006 to 2010, as well as serving as a director at other private companies
Age: 73  Director Since 2010      
650 624-3000
Costa earned both a B.S. in Pharmacy and a J.D. from St. John’s University.

Santo Costa Latest Insider Activity

Tracking and analyzing the buying and selling activities of Santo Costa against Cytokinetics stock is an integral part of due diligence when investing in Cytokinetics. Santo Costa insider activity provides valuable insight into whether Cytokinetics is net buyers or sellers over its current business cycle. Note, Cytokinetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cytokinetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Cytokinetics Management Efficiency

Cytokinetics has return on total asset (ROA) of (16.94) % which means that it has lost $16.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (120.54) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -63.24. The current Return on Average Assets is estimated to decrease to -0.33. The current Total Liabilities is estimated to increase to about 644.6 M. The current Current Liabilities is estimated to increase to about 77.5 M
The company currently holds 269.93 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. Cytokinetics has a current ratio of 7.3, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cytokinetics until it has trouble settling it off, either with new capital or with free cash flow. So, Cytokinetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytokinetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytokinetics to invest in growth at high rates of return. When we think about Cytokinetics' use of debt, we should always consider it together with cash and equity.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. Cytokinetics (CYTK) is traded on NASDAQ Exchange in USA. It is located in 350 Oyster Point Boulevard, South San Francisco, CA 94080, United States and employs 253 people. Cytokinetics is listed under Pharmaceutical Products category by Fama And French industry classification.

Cytokinetics Leadership Team

Elected by the shareholders, the Cytokinetics' board of directors comprises two types of representatives: Cytokinetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytokinetics. The board's role is to monitor Cytokinetics' management team and ensure that shareholders' interests are well served. Cytokinetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytokinetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Kaye, Director
Bradley Morgan, Senior Vice President - Drug Discovery and Early Development
Leonard Gage, Independent Chairman of the Board
Caryn McDowell, Chief Compliance Officer, Vice President General Counsel
Robert Wong, Chief Accounting Officer, Vice President
John Henderson, Independent Director
Sharon Barbari, CFO, Executive Vice President - Finance
Peter Roddy, Senior Vice President Chief Accounting Officer
Mark Schlossberg, Senior Vice President Legal and General Counsel
David Cragg, Sr. VP of HR
Elisabeth Schnieders, Senior Vice President - Business Development
Joanna Goldstein, IR Contact Officer
Wendall Wierenga, Independent Director
Santo Costa, Independent Director
Robert Califf, Director
Fady Malik, Senior Vice President - Research and Early Development
Wendell Wierenga, Independent Director
Lynne Parshall, Independent Director
Ching Jaw, CFO, Senior Vice President
Bonnie Charpentier, Sr. VP of Regulatory Affairs and Compliance
Robert Blum, CEO and President Director and Chief Executive of the Biopharmaceutical Concern
Sandford Smith, Independent Director
Andrew Wolff, Senior Vice President - Clinical Research and Development, Chief Medical Officer
Diane Weiser, IR Contact Officer

Cytokinetics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytokinetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Ceiling Movement Now


Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.